Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Federal Trade Commission
Healthtrust
Baxter
Chubb
Colorcon
QuintilesIMS
Boehringer Ingelheim
McKinsey

Generated: August 19, 2018

DrugPatentWatch Database Preview

Ipsen Inc Company Profile

« Back to Dashboard

Summary for Ipsen Inc
International Patents:55
US Patents:12
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Ipsen Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Inc ONIVYDE irinotecan hydrochloride INJECTABLE, LIPOSOMAL;IV (INFUSION) 207793-001 Oct 22, 2015 RX Yes Yes 9,782,349 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ipsen Inc ONIVYDE irinotecan hydrochloride INJECTABLE, LIPOSOMAL;IV (INFUSION) 207793-001 Oct 22, 2015 RX Yes Yes 9,724,303 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ipsen Inc ONIVYDE irinotecan hydrochloride INJECTABLE, LIPOSOMAL;IV (INFUSION) 207793-001 Oct 22, 2015 RX Yes Yes 9,452,162 ➤ Try a Free Trial ➤ Try a Free Trial
Ipsen Inc ONIVYDE irinotecan hydrochloride INJECTABLE, LIPOSOMAL;IV (INFUSION) 207793-001 Oct 22, 2015 RX Yes Yes 8,329,213 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ipsen Inc ONIVYDE irinotecan hydrochloride INJECTABLE, LIPOSOMAL;IV (INFUSION) 207793-001 Oct 22, 2015 RX Yes Yes 9,339,497 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Ipsen Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ipsen Inc INCRELEX mecasermin recombinant INJECTABLE;SUBCUTANEOUS 021839-001 Aug 30, 2005 5,681,814 ➤ Try a Free Trial
Ipsen Inc INCRELEX mecasermin recombinant INJECTABLE;SUBCUTANEOUS 021839-001 Aug 30, 2005 6,207,640 ➤ Try a Free Trial
Ipsen Inc INCRELEX mecasermin recombinant INJECTABLE;SUBCUTANEOUS 021839-001 Aug 30, 2005 5,824,642 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for Ipsen Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,658,203 Liposomes useful for drug delivery to the brain ➤ Try a Free Trial
9,737,528 Liposomes useful for drug delivery to the brain ➤ Try a Free Trial
9,717,723 Liposomes useful for drug delivery ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Ipsen Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0885 Netherlands ➤ Try a Free Trial PRODUCT NAME: ONIVYDE - IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018
2017000042 Germany ➤ Try a Free Trial PRODUCT NAME: LRINOTECAN SUCROSOFAT-SALZ, WIE Z.B. LRINOTECAN SUCROSOFAT-SALZ IN EINEM PEGYLIERTEN LIPOSOM WIE BEISPIELWEISE EINEM LIPOSOM, DAS 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLIN, CHOLESTERIN UND N-(OMEGA-METHOXYPOLY(ETHYLENGLYKOL) (MOLEKULARGEWICHT 2000)OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMIN Z.B. IM MOLVERHAELTNIS 3:2:0,015 UMFASST.; REGISTRATION NO/DATE: EU/1/16/1130 20161014
C/GB97/010 United Kingdom ➤ Try a Free Trial PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017
2017 00030 Denmark ➤ Try a Free Trial PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
McKinsey
Julphar
Fish and Richardson
Medtronic
Argus Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.